

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE


Research Funding Update for ICOC

Patricia Olson, Ph.D.
Executive Director, Scientific Activities
ICOC Meeting – May 2014
Agenda Item #7

Outline

- Current status of Research Funding
- Back-Up: Definitions

Current Funding Allocation




Category	Awarded	Concept Approved	Future Funding	Total:	% Total
Facilities/Core Resources	372.2	-	-	372.2	13.6%
Training / Career Dev.	364.6	-	73.3	437.9	15.9%
Basic Research	354.9	-	60.0	414.9	15.1%
Translational Research	283.8	35.0	40.0	358.8	13.1%
Development & Clinical Trials	493.8	342.0	199.0	1,034.8	37.7%
Multiple		31.6	-	31.6	1.2%
Strategic Reserve	-	-	95.6	95.6	3.5%
Total	\$ 1,869.3	\$ 408.6	\$ 467.9	\$ 2,745.8	100%

- \$877 MM remains to be awarded (\$408.6 MM 'Concept Approved', \$467.9 MM 'Future Funding').

Note: Assumes funding recommendations are approved by the ICOC


Awarded



Category	Awarded	Percentage
Facilities/Core Resources	372.2	19.9%
Training / Career Dev.	364.6	19.5%
Basic Research	354.9	19.0%
Translational Research	283.8	15.2%
Development & Clinical Trials	493.8	26.4%
Total	\$ 1,869.3	100%

.Note: Assumes ICOC approves new funding as recommended

Concept Approved



Category	Approved Concepts	\$ MM	Category, \$ MM
Translational Research	Tools and Technologies III	35.0	35.0
Development & Clinical Trials	Alpha Stem Cell Clinics	70.0	342.0
	Accelerated Pathway	200.0	
	Preclinical Development	40.0	
	Strategic Partnership IV	32.0	
Multiple [^]	External Innovation	15.0	31.6
	Bridging	11.5	
	Extraordinary Supplement (Major)	5.1	
Total			408.6

[^] These Award programs can fund research projects in different categories, often Translational Research or Development

Future Funding



Category	Future Funding	\$ MM	Category \$, MM
Training, Career Development	Training III (new RFA)	45.0	73.3
	Bridges II (new RFA)	26.6	
	Creativity, (new 3 yr cycle)	1.7	
Basic Research	Basic Biology VI-VII	60.0	60.0
Translational Research	ET Transition (DCF to DC)	40.0	40.0
Development & Clinical Trials	Disease Team/Strategic Partnership (clinical development)	159.0	199.0
	Preclinical Development	40.0	
Strategic Reserve		95.6	95.6
Total			467.9

.Note: Assumes ICOC approves new funding as recommended

Summary

- Research Funding Plan implements strategy to achieve mission

Back-Up




Definitions: Categories

- **Facilities/Core Resources includes:**
 - programs that result in new and remodeled facilities for stem cell research
 - programs that provide core resources for stem cell research
- **Training/Career Development:**
 - programs whose focus is broadening and/or strengthening the pool of stem cell researchers.
- **Basic Research: focus is on**
 - fostering cutting-edge research to address significant, unresolved issues in human stem cell biology that hinder the pace of discovery, and it's application towards human disease and injury

Definitions: Categories (continued)

- **Translational Research:** focus is on
 - translating the basic research discoveries to potential therapeutics
 - addressing bottlenecks to translation
- **Development and Clinical Trials:** focus is on
 - preparation for and conduct of clinical testing of stem cell-based therapeutic candidates
 - safety and Proof - of – Concept in humans
 - infrastructure for clinical applications of cell therapies

From 12/11/13 ICOC meeting: Future Funding - Approved



Category	Future Funding	\$ MM	Category \$, MM
Training, Career Development	Training III (new RFA)	45.0	73.3
	Bridges II (new RFA)	26.6	
	Creativity, (new 3 yr cycle)	1.7	
Basic Research	Basic Biology VI-VII	60.0	60.0
Translational Research	ET Transition (DCF to DC, 2 rounds)	40.0	40.0
Development & Clinical Trials	Accelerated Pathway	200.0	461.5
	Disease Team/Strategic Partnership (clinical development)	261.5	
	ET Preclinical Development		
Strategic Reserve		30.0	30.0
Total			664.8